Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Glanzmann Thrombasthenia Follow-up

  • Author: Zonera Ashraf Ali, MBBS; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
 
Updated: Mar 31, 2015
 

Further Outpatient Care

See the list below:

  • Regular dental care is recommended to avoid gingival bleeding in individuals with Glanzmann thrombasthenia.
Next

Deterrence/Prevention

See the list below:

  • Patients with Glanzmann thrombasthenia should avoid drugs that decrease platelet function or coagulation, such as the following:
    • Aspirin or other NSAIDs
    • Heparin
    • Warfarin
    • Ticlopidine or clopidogrel
    • GP IIb/IIIa antagonists, such as abciximab
    • Streptokinase, urokinase, or tissue plasminogen activator (tPA)
    • Volume expanders, such as dextran or hydroxyethyl starch
    • Dipyridamole
Previous
Next

Complications

See the list below:

  • Bleeding complications of any type
Previous
Next

Prognosis

See the list below:

  • With platelet transfusions for bleeding complications, the prognosis is generally good in those with Glanzmann thrombasthenia.
Previous
Next

Patient Education

See the list below:

  • Educate patients with Glanzmann thrombasthenia that regular dental care is necessary to avoid gingivitis and gingival bleeding.
Previous
 
Contributor Information and Disclosures
Author

Zonera Ashraf Ali, MBBS Consulting Staff, Main Line Oncology Hematology Associates, Lankenau Cancer Center

Zonera Ashraf Ali, MBBS is a member of the following medical societies: American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Marcel E Conrad, MD Distinguished Professor of Medicine (Retired), University of South Alabama College of Medicine

Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, SWOG

Disclosure: Partner received none from No financial interests for none.

Chief Editor

Srikanth Nagalla, MBBS, MS, FACP Director, Clinical Hematology, Cardeza Foundation for Hematologic Research; Assistant Professor of Medicine, Division of Hematology, Associate Program Director, Hematology/Medical Oncology Fellowship, Assistant Program Director, Internal Medicine Residency, Jefferson Medical College of Thomas Jefferson University

Srikanth Nagalla, MBBS, MS, FACP is a member of the following medical societies: American Society of Hematology, Association of Specialty Professors

Disclosure: Nothing to disclose.

Acknowledgements

Wadie F Bahou, MD Chief, Division of Hematology, Hematology/Oncology Fellowship Director, Professor, Department of Internal Medicine, State University of New York at Stony Brook

Wadie F Bahou, MD is a member of the following medical societies: American Society of Hematology

Disclosure: Nothing to disclose.

Mark J Shumate, MD, MPH Assistant Professor, Department of Internal Medicine, Division of Hematology/Oncology, Emory University School of Medicine

Mark J Shumate, MD, MPH is a member of the following medical societies: American Society of Hematology

Disclosure: Nothing to disclose.

References
  1. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990 Apr 1. 75(7):1383-95. [Medline]. [Full Text].

  2. Malik U, Dutcher JP, Oleksowicz L. Acquired Glanzmann's thrombasthenia associated with Hodgkin's lymphoma: a case report and review of the literature. Cancer. 1998 May 1. 82(9):1764-8. [Medline]. [Full Text].

  3. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006 Apr 6. 1:10. [Medline]. [Full Text].

  4. Poon MC, Zotz R, Di Minno G, et al. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol. 2006 Jan. 43(1 suppl 1):S33-6. [Medline].

  5. Poon MC. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. Vasc Health Risk Manag. 2007. 3(5):655-64. [Medline]. [Full Text].

  6. Saxena R, Kannan M. Glanzmann's thrombasthenia: an overview. Clin Appl Thromb Hemost. 2008 Oct 16. epub ahead of print. [Medline].

  7. van de Vijver E, De Cuyper IM, Gerrits AJ, Verhoeven AJ, Seeger K, Gutiérrez L, et al. Defects in Glanzmann thrombasthenia and LAD-III (LAD-1/v) syndrome: the role of integrin ß1 and ß3 in platelet adhesion to collagen. Blood. 2011 Nov 7. [Medline].

  8. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011 Dec 1. 118(23):5996-6005. [Medline].

  9. Fiore M, Pillois X, Nurden P, Nurden AT, Austerlitz F. Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. Eur J Hum Genet. 2011 Sep. 19(9):981-7. [Medline]. [Full Text].

  10. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia. 2011 Sep. 17(5):e858-69. [Medline].

  11. Tholouli E, Hay CR, O'Gorman P, Makris M. Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol. 2004 Oct. 127(2):209-13. [Medline].

  12. Kannan M, Chatterjee T, Ahmad F, Kumar R, Choudhry VP, Saxena R. Acquired Glanzmann's thrombasthenia associated with Hairy cell leukaemia. Eur J Clin Invest. 2009 Dec. 39(12):1110-1. [Medline].

  13. Rajpurkar M, Chitlur M, Recht M, Cooper DL. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature. Haemophilia. 2014 Jul. 20(4):464-71. [Medline].

  14. Ali N, Moiz B, Shaikh U, et al. Diagnostic tool for Glanzmann's thrombasthenia clinicopathologic spectrum. J Coll Physicians Surg Pak. 2008 Feb. 18(2):91-4. [Medline].

  15. Jin PP, Shen WZ, Yang F, et al. [Analysis of clinical features and genotype in three Chinese pedigrees with Glanzmann thrombasthenia]. Zhonghua Xue Ye Xue Za Zhi. 2008 Mar. 29(3):149-53. [Medline].

  16. Lombardo VT, Sottilotta G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia. Clin Appl Thromb Hemost. 2006 Jan. 12(1):115-6. [Medline].

  17. Shen WZ, Ding QL, Jin PP, et al. A novel Pro126His beta propeller mutation in integrin alphaIIb causes Glanzmann thrombasthenia by impairing progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi. Blood Cells Mol Dis. 2008 Oct 29. epub ahead of print. [Medline].

  18. Solh M, Mescher C, Klappa A, Shah S, Zantek N, Datta Y. Acquired Glanzmann's thrombasthenia with optimal response to rituximab therapy. Am J Hematol. 2011 Aug. 86(8):715-6. [Medline].

  19. Vuckovic SA. Glanzmann's thrombasthenia revisited. J Emerg Med. 1996 May-Jun. 14(3):299-303. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.